The Predictive Role of HPV Integration in HSIL and Cervical Cancer

Tongji Hospital1 site in 1 country1 target enrollmentJuly 7, 2020

ConditionsHPV Integration

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: HPV Integration
Sponsor: Tongji Hospital
Enrollment: 1
Locations: 1
Primary Endpoint: Tissue pathological diagnosis
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The stratified analysis by the level of HPV DNA integration in HSIL and cervical cancer will be drawn to explore whether the status of HPV integration makes any difference in the progression of cervical cancer. The purpose of the research is to reduce the miss of cervix lesions and prove that HPV integration detection is sensitive in cervical cancer precise screening.

Registry

clinicaltrials.gov

Start Date

July 7, 2020

End Date

June 1, 2022

Last Updated

4 years ago

Study Type

Observational

Sex

Female

Investigators

Sponsor

Tongji Hospital

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•HPV-positive patients； Patients have completed HPV detection, TCT, and HPV integration detection before surgery or biopsy； Patients with priced diagnoses accepted treatment according to ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors； Patients who are voluntary participants in this research and cooperate to follow-up with subscribing informed consent.